Apexigen (APGN) to Be Acquired by Pyxis Oncology (PYXS) at $0.64 Per Share
by Marlena Haddad on 2023-05-25 at 11:53am

Apexigen (NASDAQ: APGN), which recently combined with Brookline Capital in July 2022, announced that it will be acquired by Pyxis Oncology (NASDAQ:PYXS) in an all-stock transaction that would value it at $0.64 per share.

For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million.

Under the terms of the agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire the company. Current stockholders of Pyxis Oncology will own approximately 90% of the combined company and Apexigen’s stockholders are expected to own 10%.

Pyxis Oncology last closed at $3.34 and so the price represents a 10.4% premium over Apexigen’s last closing price of $0.58.

Apexigen and Brookline Capital originally intended to raise $73 million through the merger, but were only able to generate $19 million in gross proceeds. After just six months of being a public company, Apexigen announced that it was evaluating strategic alternatives and implementing a corporate restructuring to extend its cash runway, which resulted in laying off 55% of its team.

With a shared vision of bringing innovative solutions to oncology patients, Pyxis expects to complete the all-stock transaction with Apexigen by mid-2023. Upon closing of the transaction, the combined company will trade on Nasdaq under the ticker symbol “PYXS” and the existing Pyxis Oncology leadership team will continue to be responsible for all executive positions.

Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers and is building next-generation therapeutics that hold the potential for mono and combination therapies.

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-05-17 at 8:08am

At the SPAC of Dawn While AST Spacemobile (NASDAQ:ASTS) had the SPAC market’s biggest leap yesterday, among de-SPACs that are trading above $10, it was oil and gas firm Sable Offshore (NYSE:SOC) that had the best outing. It finished up +14% and is gaining a further +2% in the pre-market to $14.30 this morning. This...

by Kristi Marvin on 2024-05-17 at 6:30am

RF Acquisition Corp. II (NASDAQ:RFAIU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “RFAIU”, Friday, May 17, 2024. The new SPAC intends to focus its target search on businesses in Asia within the deep technology sector, including artificial intelligence, quantum computing,...

by Nicholas Alan Clayton on 2024-05-16 at 4:05pm

AST SpaceMobile (NASDAQ:ASTS) has been on +68% a tear off of its double-barreled announcement after hours yesterday that it signed a six-year commercial partnership with telecom AT&T (NYSE:T) and had beaten analyst expectations with its first quarter earnings. It has, in fact, been the best performer on the US markets throughout the afternoon outside of...

by Nicholas Alan Clayton on 2024-05-16 at 8:24am

At the SPAC of Dawn Chinese auto conglomerate Geely (HK:0175) has occupied a not insignificant portion of recent SPAC dealflow as it has turned to the vehicles to spin off a series of subsidiaries. But, this week, it veered back to the traditional IPO path. The early returns on its move to bring EV brand...

by Nicholas Alan Clayton on 2024-05-15 at 4:17pm

Global Technology I (NASDAQ:GTAC) has entered into a definitive agreement to combine with art marketplace Tyfon at an enterprise value of $434 million, or 12.7x its $34 million 2023 EBITDA. Suzhou, China-based Tyfon operates as a dealer of Chinese contemporary art, selling pieces online and through traditional exhibition methods. The combined company is expected to...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved